Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel and Carboplatin for Patients With Metastatic, Castration Resistant Prostate Cancer and Inactivated Genes in BRCA 1/2 Pathway

NCT02598895 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02598895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02598895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel and Carboplatin for Patients With Metastatic, Castration Resistant Prostate Cancer and Inactivated Genes in BRCA 1/2 Pathway
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2016
Completion date
September 14, 2021
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration levels of testosterone, castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate carcinoma metastatic in the bone, psa progression, stage iv prostate cancer